Precision Insights for AbbVie’s Value & Evidence Strategy
Harness AI-driven research methodology to uncover real-world care gaps, quantify humanistic outcomes, and support global market access across AbbVie’s Immunology, Oncology, and Neuroscience portfolios.
The Challenge
Beyond the Gold Standard: Closing the “Real-World” Care Gap
The Clinical-to-Practice Evidence Gap
While RCTs are the gold standard, they often fail to capture “hidden” patient populations whose disease remains sub-optimally controlled in real-world clinical practice, requiring a deeper look into longitudinal patient journeys.
The “Humanistic Data” Deficit
Proving value in competitive Immunology and Neuroscience markets requires moving beyond safety data to capture “Humanistic Data”—quality-of-life and economic value metrics that resonate with global payers and support patient-centric dossiers.
The HTA & Methodological Hurdle
Securing market access requires a research-grade architecture that can distinguish true care gaps from data “missingness” while providing the transparent, auditable, and reproducible evidence needed for rigorous HTA submissions.
Solving with Komodo
Delivering Remarkable Impact Through Research-Grade RWE
Quantifying Sub-Optimal Control
Use the Healthcare MapⓇ to distinguish "fine" from "clinically controlled" disease states by tracking longitudinal treatment patterns and HCRU across 330M+ lives to uncover unmet needs in IBD and Neuroscience.
Evidence Rigor & Patient-Centered Outcomes
Support Patient-Reported Outcome (PRO) strategies by leveraging MapEnhance to integrate specialty lab and EHR data—shaving 4–9 months off research timelines while generating auditable, publication-ready SQL/R code for HTA negotiations.
Advanced Economic Modeling
Achieve a 95%+ cost fill rate through proprietary imputation to accurately quantify the "Total Cost of Care" in IBD and Oncology, filling gaps caused by capitation or incomplete adjudication to support robust budget impact models.
Representative Health Equity
Ensure value stories are representative with a dataset that mirrors the U.S. Census diversity index (95–98% alignment), supporting AbbVie's mission to "leave no patient behind" through inclusive real-world evidence.
The Komodo Impact
Evidence that Influences Future Care and Policy
Auditable, Science-First Value
Transform complex RWE into “payer-ready” stories by grounding real-world effectiveness findings in the broader scientific landscape, integrating PubMed and ClinicalTrials.gov data within a research-specific architecture that avoids selection bias.
Longitudinal Precision in Care Gaps
Distinguish genuine clinical care gaps from insurance switches using a standardized 45-day gap rule to track continuous enrollment, ensuring a high-fidelity view of the patient journey for Immunology and Neuroscience therapies.
Accelerated Evidence Velocity
Transition from months of manual query cycles to an AI thought-partner (Marmot) that flags methodological trade-offs in real-time, instantly producing descriptive statistics and tables that traditionally consume weeks of research time.
Resources
Read more about how Komodo’s robust product suite can help you unlock your team’s expertise and accelerate decision-making across the enterprise.
Gain Your Velocity Advantage in the Future of Care
It starts with data that tells the whole story. Leverage Komodo’s three-pronged HEOR methodology to drive innovative approaches to care and secure the reimbursement pathways your therapies deserve.